EuroBiotech—More Articles of Note

(NS Newsflash/CC BY 2.0)

> GlaxoSmithKline offloaded its gene therapy portfolio to Orchard Therapeutics. The deal sees GSK gain a 20% stake in the gene therapy specialist and secure a stream of milestones and royalties in return for its approved portfolio and investigational pipeline. Statement

> Kenneth Newman, M.D., has resigned as Verona Pharma CMO. Release

> Genfit’s phase 3 NASH trial hit an enrollment milestone. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Nanobiotix signed up to work with MD Anderson Cancer Center on its oncology drug NBTXR3. Release 

> Pharnext raised €16 million ($20 million) in a private placement. Statement

> Argenx cleared the third preclinical milestone in its ARGX-112 collaboration with LEO Pharma. Release

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.